How are peptide-based obesity drugs reshaping the metabolic drug pipeline?

STAT’s report highlights how peptide therapeutics are becoming central in obesity drug development, drawing strong investor interest and record IPOs. As dozens of candidates advance, FDA review standards and safety expectations will determine which stand out, influencing pricing, payer strategies, and market differentiation.